Page 129 - Human Use News Today

Nuvaxovid COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 in Europe GAITHERSBURG, Md., July 5, 2022 /PRNewswire/ -- Novavax,Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the European Commission (EC) has approved the expanded conditional marketing authorization (CMA) of Nuvaxovid (NVX-CoV2373) COVID-19 vaccine in the European Union (EU) fo...

ObsEva (OBSV) trades at a very low share price. Read why I believe there is great potential and OBSV stock is a great long-term buy.

ICH has revised Q9 Quality Risk Management, and it provides principles and tools for quality risk management that can be applied throughout the...

/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recently adopted positive opinions for three biosimilar products. On June 23, 2022, CHMP...

WASHINGTON (dpa-AFX) - Biotechnology company Novavax, Inc. (NVAX) announced Tuesday that the European Commission (EC) has approved the expanded conditional marketing authorization (CMA) of Nuvaxovid

Nuvaxovid COVID-19 vaccine is the first protein-based option for adolescents aged 12 through 17 in EuropeGAITHERSBURG, Md., July 5, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology

Albireo Pharma CEO Ron Cooper discusses the company’s three approaches to commercializing orphan drugs globally, and how to go from topline...

Nexviadyme® (avalglucosidase alfa) approved by European Commission as a potential new standard of care for the treatment of Pompe Disease

A journal of Art, Culture and Politics, Published by the University of Chicago